Editas Medicine [EDIT] vs Silence Therapeutics [SLN] Detailed Stock Comparison

Editas Medicine

NASDAQ

Silence Therapeutics

NASDAQ

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Editas Medicine wins in 5 metrics, Silence Therapeutics wins in 12 metrics, with 0 ties. Silence Therapeutics appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric	Editas Medicine	Silence Therapeutics	Better
P/E Ratio (TTM)	-0.86	-4.86	Silence Therapeutics
Price-to-Book Ratio	11.68	2.41	Silence Therapeutics
Debt-to-Equity Ratio	110.14	0.00	Silence Therapeutics
PEG Ratio	0.04	-0.14	Silence Therapeutics
EV/EBITDA	-0.48	-7.96	Silence Therapeutics
Profit Margin (TTM)	0.00%	-291.24%	Editas Medicine
Operating Margin (TTM)	-711.63%	-9,048.21%	Editas Medicine
Return on Equity	-188.58%	-66.96%	Silence Therapeutics
Return on Assets (TTM)	-33.76%	-22.25%	Silence Therapeutics
Free Cash Flow (TTM)	$-219.11M	$-67.85M	Silence Therapeutics
1-Year Return	-31.28%	-74.80%	Editas Medicine
Price-to-Sales Ratio (TTM)	5.94	8.36	Editas Medicine
Enterprise Value	$73.73M	$567.43M	Silence Therapeutics
EV/Revenue Ratio	1.90	20.89	Editas Medicine
Gross Profit Margin (TTM)	N/A	62.05%	N/A
Revenue per Share (TTM)	$0	$1	Silence Therapeutics
Earnings per Share (Diluted)	$-2.84	$-1.68	Silence Therapeutics
Beta (Stock Volatility)	2.20	1.39	Silence Therapeutics

Performance

Key Stats

Valuation

Financials

Short Interest

Dividends

Editas Medicine vs Silence Therapeutics Stock Performance Analysis

Loading Price Chart...

Performance Comparison

Short-term Returns

Stock	1D	1W	1M	3M	6M	YTD
Editas Medicine	-3.02%	-8.21%	-0.77%	40.44%	33.85%	96.18%
Silence Therapeutics	-5.69%	-10.09%	-22.42%	-19.02%	6.89%	-33.10%

Long-term Returns

Stock	1Y	3Y	5Y	10Y	15Y	20Y
Editas Medicine	-31.28%	-82.67%	-91.57%	-85.40%	-85.40%	-85.40%
Silence Therapeutics	-74.80%	-54.58%	-75.33%	-75.33%	-75.33%	-75.33%

Performance & Financial Health Analysis: Editas Medicine vs Silence Therapeutics

Metric	EDIT	SLN
Market Information
Market Cap i	$146.11M	$203.97M
Market Cap Category	Micro cap	Micro cap
10 Day Avg. Volume i	1,079,030	41,090
90 Day Avg. Volume i	2,023,140	65,773
Last Close	$2.57	$4.81
52 Week Range	$0.91 - $4.12	$1.97 - $20.48
% from 52W High	-37.62%	-76.51%
All-Time High	$99.95 (Jan 04, 2021)	$35.00 (May 24, 2021)
% from All-Time High	-97.43%	-86.26%
Growth Metrics
Quarterly Revenue Growth	5.98%	-0.70%
Quarterly Earnings Growth	5.97%	-0.70%
Financial Health
Profit Margin (TTM) i	0.00%	-2.91%
Operating Margin (TTM) i	-7.12%	-90.48%
Return on Equity (TTM) i	-1.89%	-0.67%
Debt to Equity (MRQ) i	110.14	0.00
Cash & Liquidity
Book Value per Share (MRQ)	$0.22	$1.99
Cash per Share (MRQ)	$1.99	$0.81
Operating Cash Flow (TTM) i	$-201,360,992	$-87,181,000
Levered Free Cash Flow (TTM) i	$-78,909,872	$-39,052,924
Dividends
Last 12-Month Dividend Yield i	N/A	N/A
Last 12-Month Dividend i	N/A	N/A

Valuation & Enterprise Metrics Analysis: Editas Medicine vs Silence Therapeutics

Metric	EDIT	SLN
Price Ratios
P/E Ratio (TTM) i	-0.86	-4.86
Forward P/E i	-1.09	-6.41
PEG Ratio i	0.04	-0.14
Price to Sales (TTM) i	5.94	8.36
Price to Book (MRQ) i	11.68	2.41
Market Capitalization
Market Capitalization i	$146.11M	$203.97M
Enterprise Value i	$73.73M	$567.43M
Enterprise Value Metrics
Enterprise to Revenue i	1.90	20.89
Enterprise to EBITDA i	-0.48	-7.96
Risk & Other Metrics
Beta i	2.20	1.39
Book Value per Share (MRQ) i	$0.22	$1.99

Financial Statements Comparison: Editas Medicine vs Silence Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)	EDIT	SLN
Revenue/Sales i	$4.66M	$224,000
Cost of Goods Sold i	N/A	$85,000
Gross Profit i	N/A	$139,000
Research & Development i	$26.59M	$17.65M
Operating Income (EBIT) i	$-35.31M	$-22.64M
EBITDA i	$-31.10M	$-14.55M
Pre-Tax Income i	$-76.09M	$-27.34M
Income Tax i	N/A	$10,000
Net Income (Profit) i	$-76.09M	$-27.35M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)	EDIT	SLN
Cash & Equivalents i	$138.69M	$41.74M
Total Current Assets i	$224.84M	$148.55M
Total Current Liabilities i	$73.11M	$14.77M
Long-Term Debt i	$17.97M	N/A
Total Shareholders Equity i	$62.42M	$94.16M
Retained Earnings i	$-1.54B	$-529.84M
Property, Plant & Equipment i	$47.50M	$1.83M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)	EDIT	SLN
Operating Cash Flow i	$-52.70M	$-25.24M
Capital Expenditures i	$-114,000	$-48,000
Free Cash Flow i	$-47.91M	$-21.83M
Debt Repayment i	N/A	N/A
Common Stock Repurchase i	N/A	N/A

Short Interest & Institutional Ownership Analysis

Metric	EDIT	SLN
Shares Short i	8.20M	770,450
Short Ratio i	3.37	9.84
Short % of Float i	0.09%	0.02%
Average Daily Volume (10 Day) i	1,079,030	41,090
Average Daily Volume (90 Day) i	2,023,140	65,773
Shares Outstanding i	82.73M	141.67M
Float Shares i	89.58M	74.75M
% Held by Insiders i	0.00%	0.24%
% Held by Institutions i	0.49%	0.44%

Dividend Analysis & Yield Comparison: Editas Medicine vs Silence Therapeutics

Metric	EDIT	SLN
Last 12-Month Dividend i	N/A	N/A
Last 12-Month Dividend Yield i	N/A	N/A
3-Year Avg Annual Dividend i	N/A	N/A
3-Year Avg Dividend Yield i	N/A	N/A
3-Year Total Dividends i	N/A	N/A
Ex-Dividend Date	N/A	N/A